利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1081 条记录 (耗时 0.024 秒)

    NUCLEIC ACID COMPOUNDS FOR INHIBITING HRAS GENE EXPRESSION AND USES THEREOF
    53.
    发明申请
    NUCLEIC ACID COMPOUNDS FOR INHIBITING HRAS GENE EXPRESSION AND USES THEREOF 审中-公开
    用于抑制人源基因表达的核酸化合物及其用途

    公开(公告)号：WO2011133584A3

    公开(公告)日：2012-01-12

    申请号：PCT/US2011033102

    申请日：2011-04-19

    申请人： MARINA BIOTECH INC ,  VAISH NARENDRA K ,  SETH SHAGUNA ,  FOSNAUGH KATHY L ,  HOUSTON MICHAEL E ,  TEMPLIN MICHAEL V

    发明人： VAISH NARENDRA K ,  SETH SHAGUNA ,  FOSNAUGH KATHY L ,  HOUSTON MICHAEL E ,  TEMPLIN MICHAEL V

    IPC分类号： C12N15/113 ,  A61P35/00

    CPC分类号： C12N15/1135 ,  C12N2310/14 ,  C12N2310/321 ,  C12N2310/344 ,  C12N2310/3521

    摘要： This disclosure provides double- stranded nucleic acid complexes having one or more hydroxymethyl substituted nucleomonomer(s) and wherein one strand is complementary to a HRAS mRNA. Nucleic acid complexes of the disclosure may be useful for therapeutic applications, diagnostic applications or research applications. Nucleic complexes include short interfering RNA complexes (siRNA) capable of modulating gene expression comprising an antisense strand and a continuous or a discontinuous passenger strand ("sense strand"). Further, one or more hydroxymethyl substituted nucleomonomer(s) of this disclosure may be positioned at the 3 '-end, at the 5 '-end, at both the 3 '-end and 5 'end, and/or in a double-stranded region of a nucleic acid complex. Also provided are methods of decreasing expression of a HRAS gene in a cell or in a subject to treat a HRAS-related disease.

    摘要翻译： 本公开提供了具有一个或多个羟甲基取代的核小体单体的双链核酸复合物，其中一条链与HRAS mRNA互补。 本公开的核酸复合物可用于治疗应用，诊断应用或研究应用。 核复合物包括能够调节包含反义链和连续或不连续乘客链（“有义链”）的基因表达的短干扰RNA复合物（siRNA）。 此外，本公开的一个或多个羟甲基取代的核小体单体可以位于3'端，5“端，3”端和5“端，和/ 核酸复合物的双链区。 还提供减少细胞或受试者中HRAS基因表达以治疗HRAS相关疾病的方法。

    PHARMACEUTICAL COMPOSITION FOR INHIBITING ABNORMAL PROLIFERATION OF CELLS
    54.
    发明申请
    PHARMACEUTICAL COMPOSITION FOR INHIBITING ABNORMAL PROLIFERATION OF CELLS 审中-公开
    用于抑制细胞异常增殖的药物组合物

    公开(公告)号：WO2011096756A3

    公开(公告)日：2011-12-15

    申请号：PCT/KR2011000768

    申请日：2011-02-07

    申请人： UNIV EWHA IND COLLABORATION ,  KANG SANG WON ,  LEE SOO YOUNG

    发明人： KANG SANG WON ,  LEE SOO YOUNG

    IPC分类号： A61K38/16 ,  A61P35/00 ,  C12N15/11 ,  G01N33/15

    CPC分类号： C12N15/1135 ,  A61K39/00 ,  C12N2310/11

    摘要： The present invention relates to a pharmaceutical composition for preventing or treating diseases related to abnormal proliferation of cells, comprising a cytoplasmic heat shock protein (Hsp)60 kDa inhibitor as an active ingredient, and to a screening method and a kit using the composition. According to the present invention, substances which inhibit expression of cytoplasmic Hsp 60 genes or inhibit activity of cytoplasmic Hsp 60 or inhibit binding between cytoplasmic Hsp 60 and IKK protein prevent interaction between cytoplasmic Hsp 60 and IKK complexes to make NF- ?B path inactive, and thus induce apoptosis. Therefore, the substances can be valuably used in preventing or treating diseases related to abnormal proliferation of cells, such as cancer, inflammatory diseases or hyperproliferative vascular diseases.

    摘要翻译： 本发明涉及用于预防或治疗与细胞异常增殖有关的疾病的药物组合物，其包含细胞质热休克蛋白（Hsp）60kDa抑制剂作为活性成分，以及使用该组合物的筛选方法和试剂盒。 根据本发明，抑制细胞质Hsp 60基因表达或抑制细胞质Hsp60活性或抑制细胞质Hsp60与IKK蛋白之间结合的物质可防止细胞质Hsp60与IKK复合体之间的相互作用，使NF-κB通路无活性， 从而诱导凋亡。 因此，这些物质可以有效地用于预防或治疗与癌症，炎性疾病或过度增生性血管疾病等细胞的异常增殖有关的疾病。

    SIRNA FOR INHIBITING C-MET EXPRESSION AND AN ANTI-CANCER COMPOSITION COMPRISING THE SAME
    55.
    发明申请
    SIRNA FOR INHIBITING C-MET EXPRESSION AND AN ANTI-CANCER COMPOSITION COMPRISING THE SAME 审中-公开
    用于抑制C-MET表达的SIRNA和包含其的抗癌组合物

    公开(公告)号：WO2011081415A3

    公开(公告)日：2011-12-01

    申请号：PCT/KR2010009440

    申请日：2010-12-28

    申请人： SAMYANG CORP ,  KIM SUN-OK ,  KIM SANG-HEE ,  CHO EUN-AH ,  IN CHANG-HOON

    发明人： KIM SUN-OK ,  KIM SANG-HEE ,  CHO EUN-AH ,  IN CHANG-HOON

    IPC分类号： C12N15/11 ,  A61K31/7105 ,  A61P35/00 ,  C12N15/63

    CPC分类号： A61K31/7105 ,  A61K31/713 ,  C12N15/1135 ,  C12N2310/14

    摘要： The present invention provides a small interfering ribonucleic acid (siRNA) which is complementarily bonded to a base sequence of c-Met transcript (mRNA transcript) to suppress c-Met expression in a cell as well as optionally to not induce immunological reactions, and applications of the siRNA for cancer prevention and/or treatment. The siRNA, which is bonded complementarily to the mRNA involved in the encryption of the c-Met, suppresses c-Met expression which is overexpressed in nearly all cancer cells in common due to the RNA interference (RNAi) phenomenon and inhibits the proliferation and metastasis of the cancer cells, thereby making the siRNA very useful as an anticancer agent.

    摘要翻译： 本发明提供了与c-Met转录物（mRNA转录物）的碱基序列互补结合以抑制细胞中c-Met表达以及任选地不诱导免疫反应的小干扰性核糖核酸（siRNA）和应用 的用于癌症预防和/或治疗的siRNA。 与参与c-Met加密的mRNA互补键合的siRNA抑制由于RNA干扰（RNAi）现象而在几乎所有癌细胞中过表达的c-Met表达，并抑制增殖和转移 的癌细胞，从而使siRNA非常有用作抗癌剂。

    NUCLEIC ACID COMPOUNDS FOR INHIBITING HRAS GENE EXPRESSION AND USES THEREOF
    57.
    发明申请
    NUCLEIC ACID COMPOUNDS FOR INHIBITING HRAS GENE EXPRESSION AND USES THEREOF 审中-公开
    用于抑制人源基因表达的核酸化合物及其用途

    公开(公告)号：WO2011133584A2

    公开(公告)日：2011-10-27

    申请号：PCT/US2011/033102

    申请日：2011-04-19

    申请人： MARINA BIOTECH, INC. ,  VAISH, Narendra, K. ,  SETH, Shaguna ,  FOSNAUGH, Kathy, L. ,  HOUSTON, Michael, E. ,  TEMPLIN, Michael, V.

    发明人： VAISH, Narendra, K. ,  SETH, Shaguna ,  FOSNAUGH, Kathy, L. ,  HOUSTON, Michael, E. ,  TEMPLIN, Michael, V.

    IPC分类号： C12N15/113 ,  A61P35/00

    CPC分类号： C12N15/1135 ,  C12N2310/14 ,  C12N2310/321 ,  C12N2310/344 ,  C12N2310/3521

    摘要： This disclosure provides double- stranded nucleic acid complexes having one or more hydroxymethyl substituted nucleomonomer(s) and wherein one strand is complementary to a HRAS mRNA. Nucleic acid complexes of the disclosure may be useful for therapeutic applications, diagnostic applications or research applications. Nucleic complexes include short interfering RNA complexes (siRNA) capable of modulating gene expression comprising an antisense strand and a continuous or a discontinuous passenger strand ("sense strand"). Further, one or more hydroxymethyl substituted nucleomonomer(s) of this disclosure may be positioned at the 3 '-end, at the 5 '-end, at both the 3 '-end and 5 'end, and/or in a double-stranded region of a nucleic acid complex. Also provided are methods of decreasing expression of a HRAS gene in a cell or in a subject to treat a HRAS-related disease.

    摘要翻译： 本公开提供了具有一个或多个羟甲基取代的核小体单体的双链核酸复合物，其中一条链与HRAS mRNA互补。 本公开的核酸复合物可用于治疗应用，诊断应用或研究应用。 核复合物包括能够调节包含反义链和连续或不连续乘客链（“有义链”）的基因表达的短干扰RNA复合物（siRNA）。 此外，本公开的一个或多个羟甲基取代的核小体单体可以位于3'端，5“端，3”端和5“端，和/ 核酸复合物的双链区。 还提供减少细胞或受试者中HRAS基因表达以治疗HRAS相关疾病的方法。

    RNA APTAMERS AGAINST BAFF-R AS CELL-TYPE SPECIFIC DELIVERY AGENTS AND METHODS FOR THEIR USE
    58.
    发明申请
    RNA APTAMERS AGAINST BAFF-R AS CELL-TYPE SPECIFIC DELIVERY AGENTS AND METHODS FOR THEIR USE 审中-公开
    RNA APTAMERS反对BAFF-R作为细胞型特异性递送剂及其使用方法

    公开(公告)号：WO2011130458A2

    公开(公告)日：2011-10-20

    申请号：PCT/US2011/032385

    申请日：2011-04-13

    申请人： ROSSI, John ,  ZHOU, Jeihua ,  HOHN, Britta ,  HERGENREIDER, Eduard ,  TEIMANN, Katrin

    发明人： ROSSI, John ,  ZHOU, Jeihua ,  HOHN, Britta ,  HERGENREIDER, Eduard ,  TEIMANN, Katrin

    IPC分类号： A61K48/00

    CPC分类号： C12N15/115 ,  A61K31/713 ,  A61K47/48092 ,  A61K47/549 ,  C07H21/02 ,  C12N15/111 ,  C12N15/1135 ,  C12N2310/14 ,  C12N2310/16 ,  C12N2310/3519 ,  C12N2310/51 ,  C12N2320/32

    摘要： In one embodiment, a B cell specific aptamer-siRNA chimera is provided. The B cell specific aptamer-siRNA chimera may include an RNA aptamer that binds BAFF-R and an siRNA molecule conjugated to the RNA aptamer via a nucleotide linker. In another embodiment, a B cell specific RNA aptamer is provided. The RNA aptamer may be a molecule that binds to BAFF-R that has the sequence SEQ ID NO:37, SEQ ID NO:38 or SEQ ID NO:39. In some embodiments, the RNA aptamer is conjugated, via a nucleotide linker, to an siRNA molecule that suppresses expression of one or more target oncogenes in one or more B cells. In one aspect, the one or more target oncogenes are selected from Bcl6, Bcl2, STAT3, Cyclin D1, Cyclin E2 and c-myc. In another embodiment, methods for treating a B cell malignancy in a cancer patient are provided. Such methods may include administering a therapeutically effective amount of a therapeutic composition, the therapeutic composition comprising a B cell specific RNA aptamer that binds BAFF-R.

    摘要翻译： 在一个实施方案中，提供了B细胞特异性适体 - siRNA嵌合体。 B细胞特异性适体 - siRNA嵌合体可以包括通过核苷酸接头结合BAFF-R的RNA适配体和与RNA适体结合的siRNA分子。 在另一个实施方案中，提供了B细胞特异性RNA适体。 RNA适体可以是结合具有序列SEQ ID NO：37，SEQ ID NO：38或SEQ ID NO：39的BAFF-R的分子。 在一些实施方案中，RNA适体通过核苷酸接头与抑制一种或多种B细胞中一种或多种靶致癌基因表达的siRNA分子缀合。 一方面，一种或多种靶致癌基因选自Bcl6，Bcl2，STAT3，细胞周期蛋白D1，细胞周期蛋白E2和c-myc。 在另一个实施方案中，提供了用于治疗癌症患者中的B细胞恶性肿瘤的方法。 这样的方法可以包括施用治疗有效量的治疗组合物，所述治疗组合物包含结合BAFF-R的B细胞特异性RNA适体。